Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468689 · ClinicalTrials.gov registry record · Phase 1
Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00468689 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 15 participants.
The verdict
NCT00468689, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and exposure of SB-751689 when administered alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a PGP/CYP3A4 inhibitor that increases exposure of SB-751689. Data from this study will enable the planning and conduct of a QTc study for SB-751689.
Interventions
- DRUG SB-751689 oral tablets (100 and 400 ng)
- DRUG Ketoconazole (NIZORAL) oral tablets (200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468689
The ClinicalTrials.gov registry entry for NCT00468689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SB-751689 oral tablets (100 and 400 ng) is the first listed.
NCT00468689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00468689 about?
NCT00468689 is a clinical study titled "Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.". This study will evaluate the safety, tolerability and exposure of SB-751689 when administered alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a PGP/CYP3A4 inhibitor that increases exposure of SB-751689. Data from this study will enable the planning and conduc...
What is the current status of trial NCT00468689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00468689?
The interventions under investigation include: SB-751689 oral tablets (100 and 400 ng) (DRUG), Ketoconazole (NIZORAL) oral tablets (200 mg) (DRUG).
Who is sponsoring clinical trial NCT00468689?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.